Translation of Nanotechnology in Cancer (TONIC)

At a Glance
  • Status: Active Consortium
  • Year Launched: 2011
  • Initiating Organization: National Cancer Institute
  • Initiator Type: Government
  • Disease focus:
  • Location: North America


In 2011, the National Cancer Institute (NCI) initiated a public-private industry partnership called Translation of Nanotechnology in Cancer (TONIC) to accelerate the translation and development of nanotechnology solutions for the early detection, diagnosis, and treatment of cancer. The TONIC consortium, composed of government entities and pharmaceutical, biotechnology, and other healthcare-related companies, works in parallel to the NCI Alliance for Nanotechnology in Cancer. The consortium seeks to evaluate promising nanotechnology platforms and facilitate their successful translation from academic research to the clinic, resulting in safe, timely, effective, and novel diagnosis and treatment options for patients. By encouraging mutual collaborations between Alliance investigators and industry partners on both precompetitive and late-stage programs, TONIC stands to promote the qualification, development, and regulatory acceptance of nanotechnologies in cancer.


Specifically, the TONIC consortium is tasked with the following:

Points of Contact

Christopher Hartshorn

Sponsors & Partners

National Cancer Institute, National Institutes of Health

Last Updated: 04/07/2016

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.